Tens of thousands of people with type I diabetes across the country are to benefit from “life-changing” glucose monitors on the NHS, NHS England has announced on World Diabetes Day.
News
UK launch for Mylan, Biocon insulin glargine biosimilar Semglee
Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Pfizer loses landmark second medical use patent case
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
The Sales Awards ceremony draws closer – don’t miss out on the chance to book tickets
The PharmaTimes Sales Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this ceremony that celebrates the very best the industry has to offer.
The Marketer of the Year awards ceremony draws closer – don’t miss out on the chance to book tickets
The PharmaTimes Marketer of the Year Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this special 25th anniversary ceremony that celebrates the very best the industry has to offer.
The Communications Team of the Year awards ceremony draws closer – don’t miss out on the chance to book tickets
The PharmaTimes Communications of the Year Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this ceremony that celebrates the very best the industry has to offer.
SMC endorses EUSA Pharma’s Qarziba
A medicine used to treat a rare cancer that predominantly occurs in very young children is to be routinely funded on the NHS in Scotland.
Oxford BioDynamics signs deal to develop ASD biomarkers
Oxford BioDynamics, Italian research institute pair to develop biomarkers for autism spectrum disorder (ASD).
Evox bags grant from Duchenne UK to engineer exosomes
Evox Therapeutics has secured £655,000 in funding from Duchenne UK, to support exploration of its exosome-based therapeutic platform for the condition.
AstraZeneca divests US rights to Synagis
Swedish Orphan Biovitrum AB has entered into an agreement to buy US rights to AstraZeneca’s Synagis, licensed for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV).
England sees “steep rise” in measles cases
Public Health England is urging the public to ensure they have had two doses of MMR vaccine after outbreaks of measles are confirmed across England.
EU expands label of GSK/Innoviva’s COPD inhaler
The European Commission expanded the scope of GlaxoSmithKline/Innoviva’s once-daily Trelegy Ellipta to reach more patients with COPD.
MSD’s Keytruda approved for liver cancer
US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Priority review for AZ/MSD’s Lynparza in first-line maintenance setting
US regulators have accepted an application from AstraZeneca and MSD for use of Lynparza as maintenance treatment for patients with newly-diagnosed, BRCA-mutated advanced ovarian cancer.
MPs order release of documents on negotiations for Vertex’ CF drugs
The UK House of Commons’ Health and Social Care Committee has requested documents and evidence from Vertex Pharmaceuticals, NHS England and the National Institute for Health and Care Excellence (NICE) regarding ongoing and lengthy negotiations about NHS funding for the firm’s cystic fibrosis treatments.
